SAB Biotherapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Chardan 10th Annual Healthcare Conference on October 20, 2026. CEO Samuel J. Reich will present a fireside chat discussing the company's lead drug candidate, SAB-142, which targets autoimmune type 1 diabetes (T1D) with a novel therapeutic approach. SAB-142 is currently in a Phase 2b clinical trial aiming to delay onset and prevent progression of Stage 3 T1D. This event offers SAB BIO a platform to engage investors and showcase its innovative treatment developments using genetically engineered transchromosomic cattle to produce human immunoglobulin G (hIgG).
SAB BIO's participation in the Chardan 10th Annual Healthcare Conference provides context for health sector trading activity on Pluang. For readers following healthcare stocks, here is Pluang's market snapshot as of Oct 14, 2026 19:01 WIB: Among 150 priced health-sector US stocks, 105 rose and 40 fell today. Arrowhead Pharmaceuticals (ARWR) gained 6.62% to USD 61.98 with a typical hold time of 5 days, while Enveric Biosciences (ENVB) declined 4.29% to USD 1.34, held typically for 14 days. ClearPoint Neuro (CLPT) rose 3.36% to USD 10.14, with all Pluang order activity buying and a typical hold time of 10 days.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
